This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence of enhanced efficacy in pharmaceutical patent applications.
Read more about Pfizer falls prey to Section 3(d)Tag: Patentability
ECJ Stems “Stem Cell” Patents
The ECJ has held that patents involving embryonic stem cells requiring destruction of human embryos are unpatentable in Europe. This post examines the legal and ethical reasoning behind the ruling and its implications for biotechnological innovation and patent law.
Read more about ECJ Stems “Stem Cell” Patents